Education
About Us
Working with TipRanks
Follow Us
Veru Inc (VERU)
NASDAQ:VERU
VERU Stock Chart & Stats
$2.39
-$0.01(-1.91%)
At close: 4:00 PM EST
$2.39
-$0.01(-1.91%)
Day’s Range― - ―
52-Week Range$2.10 - $7.41
Previous CloseN/A
Volume1.22M
Average Volume (3M)126.12K
Market Cap
$37.08M
Enterprise Value$5.94M
Total Cash (Recent Filing)$32.99M
Total Debt (Recent Filing)$2.98M
Price to Earnings (P/E)―
Beta0.21
Next Earnings
May 07, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding16,050,320
10 Day Avg. Volume95,433
30 Day Avg. Volume126,116
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)3.04
Price to Sales (P/S)0.00
P/FCF Ratio-1.85
Enterprise Value/Market Cap0.16
Enterprise Value/Revenue24.04
Enterprise Value/Gross Profit-68.08
Enterprise Value/Ebitda-1.30
Forecast
1Y Price Target
$25.00Price Target Upside946.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.3
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Study SuccessThe Ph. IIb QUALITY study has achieved full enrollment of over 150 patients, with top-line data expected to provide insights into enobosarm's effectiveness.
Potential PartnershipsPositive results from the QUALITY trial could help the company secure a partnership before advancing enobosarm into a pivotal program for the treatment of obesity.
Strategic Business MovesVERU has strategically monetized its FC2 female condom business for $18M to focus solely on enobosarm's development.
Bears Say
Market CompetitionThe ease of administration for enobosarm (an oral drug) compares favorably to other competing treatment options that require intravenous administration.
Stock VolatilityA significant intra-day stock sell-off was attributed to the lack of meaningful weight loss benefits observed during the initial period of the study.
Study ChallengesThe ongoing Phase 2b QUALITY trial of enobosarm in combination with Wegovy (semaglutide) for the treatment of sarcopenic obesity is on track to report topline data in January 2025.
Veru News
VERU FAQ
What was Veru Inc’s price range in the past 12 months?
Veru Inc lowest stock price was $2.10 and its highest was $7.41 in the past 12 months.
What is Veru Inc’s market cap?
Veru Inc’s market cap is $37.08M.
When is Veru Inc’s upcoming earnings report date?
Veru Inc’s upcoming earnings report date is May 07, 2026 which is in 83 days.
How were Veru Inc’s earnings last quarter?
Veru Inc released its earnings results on Feb 11, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.472 by $0.212.
Is Veru Inc overvalued?
According to Wall Street analysts Veru Inc’s price is currently Undervalued.
Does Veru Inc pay dividends?
Veru Inc pays a Quarterly dividend of $0.07 which represents an annual dividend yield of N/A. See more information on Veru Inc dividends here
What is Veru Inc’s EPS estimate?
Veru Inc’s EPS estimate is -0.29.
How many shares outstanding does Veru Inc have?
Veru Inc has 16,050,320 shares outstanding.
What happened to Veru Inc’s price movement after its last earnings report?
Veru Inc reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.472. Following the earnings report the stock price went down -8.607%.
Which hedge fund is a major shareholder of Veru Inc?
Currently, no hedge funds are holding shares in VERU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Veru Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.00 (946.03% Upside)
$25.00 (946.03% Upside)
Blogger Sentiment
Bullish
VERU Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 653.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 9.6%
Last 30 Days ▼ 9.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.96%
12-Months-Change
Fundamentals
Return on Equity
-61.92%
Trailing 12-Months
Asset Growth
-50.94%
Trailing 12-Months
Company Description
Veru Inc
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
VERU Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed multiple substantive positives: a supportive FDA meeting clarifying development pathways, positive Phase 2b proof-of-concept data for Novosarm, an attractive BMD surrogate endpoint opportunity, a planned Phase 2b PLATO study with defined endpoints, and improved liquidity after a $23.4M financing that increased cash to ~$33M and materially improved working capital and operating expense trends. Offsetting risks include the company remaining unprofitable, reliance on cash through the interim analysis (creating near-term financing risk), conditional regulatory approval criteria if incremental weight loss is under 5%, nonrecurring prior-period gains, and long timelines to meaningful readouts (interim not expected until 2027). Overall, the highlights and strengthened balance sheet and regulatory clarity meaningfully outweigh the lowlights, but execution and further financing remain key risks.View all VERU earnings summariesVERU Stock 12 Month Forecast
Average Price Target
$25.00
▲(946.03% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Cue Biopharma
―
Inmune Bio
―
Celularity
―
Jupiter Neurosciences, Inc.
―
Ownership Overview
Currently, No data available
---